抗抑郁药说明书警示语及预防措施分析

doi:10.19803/j.1672-8629.20240826

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (3): 329-333.
DOI: 10.19803/j.1672-8629.20240826

抗抑郁药说明书警示语及预防措施分析

邹远磊^1,2, 夏清荣³, 梁俊^1,*, 何孔亮⁴, 莫大明⁵, 吴文宁²

¹安徽医科大学附属心理医院,安徽省精神卫生中心,合肥市第四人民医院药剂科,安徽合肥 230022;
²安徽医科大学基础医学院药理学教研室,安徽合肥 230031;
³安徽医科大学附属心理医院,安徽省精神卫生中心,合肥市第四人民医院精神药理研究室,安徽合肥 230022;
⁴安徽医科大学附属心理医院,安徽省精神卫生中心,合肥市第四人民医院心理咨询中心,安徽合肥 230022;
⁵安徽医科大学附属心理医院,安徽省精神卫生中心,合肥市第四人民医院儿童青少年心理科,安徽合肥 230022

收稿日期:2024-11-03 出版日期:2025-03-15 发布日期:2025-03-17
通讯作者: ^*梁俊,女,硕士,主任药师,临床药学与精神病学。E-mail:1309071273@qq.com
作者简介:邹远磊,男,硕士,副主任药师,药学与神经药理学。
基金资助:
国家自然科学基金资助项目（82171449）;合肥市第七周期重点专科资助

Words of Warning and Preventive Measures in Labels of Antidepressants

ZOU Yuanlei^1,2, XIA Qingrong³, LIANG Jun^1,*, HE Kongliang⁴, MO Daming⁵, WU Wenning²

¹Department of Pharmacy, HefeiAnhui 230022, China;
²Department of Pharmacology, School of Basic Medicine, Anhui Medical University, Hefei Anhui 230031, China;
³Department of Psychopharmacology Research Laboratory, Hefei Anhui 230022, China;
⁴Psychological Counseling Center, Hefei Anhui 230022, China;
⁵Department of Child and Adolescent Psychology, Affiliated Psychological Hospital of Anhui Medical University, Anhui Mental Health Center, Hefei Fourth People's Hospital, Hefei Anhui 230022, China

Received:2024-11-03 Online:2025-03-15 Published:2025-03-17

摘要/Abstract

摘要： 目的分析某精神专科三甲医院抗抑郁药说明书警示语及预防措施,为抗抑郁药说明书警示语及预防措施的规范书写提供参考。方法统计安徽医科大学附属心理医院2022年9月1日至2022年9月30日期间抗抑郁药说明书警示语及预防措施的频数,分析警示语及预防措施现状。结果 19种抗抑郁药说明书纳入统计,说明书有警示语的总频数共33,对应预防措施的总频数为33,3种警示语中说明书无对应警示语的总频数10;警示语内容完善的总频数为17,预防措施内容完善的总频数为22。警示语出现的频数情况为“自杀倾向和抗抑郁药物”30（90.91%）,“乙肝病毒患者/携带者、丙肝病毒患者/携带者、肝功能损害患者或转氨酶升高超过正常上限者禁用”2（6.06%）,“癫痫、青光眼、尿潴留、近期有心肌梗死发作史、对本品过敏者禁用”1（3.03%）。警示语对应的预防措施频数为“自杀倾向和抗抑郁药物”预防措施30（90.91%）,“乙肝病毒患者/携带者、丙肝病毒患者/携带者、肝功能损害患者或转氨酶升高超过正常上限者禁用”预防措施2（6.06%）,“癫痫、青光眼、尿潴留、近期有心肌梗死发作史、对本品过敏者禁用”预防措施1（3.03%）。结论 “自杀倾向和抗抑郁药物”和“癫痫、青光眼、尿潴留、近期有心肌梗死发作史、对本品过敏者禁用”警示语及预防措施存在缺失和不完善现象,建议相关生产企业补充缺失的警示语及预防措施,“自杀倾向和抗抑郁药物”警示语及预防措施中明确青年患者自杀倾向易发人群的年龄范围,完善“警示语内容解释说明”“病史筛查”“自杀先兆症状描述”“改变药物治疗描述”等预防措施内容。

关键词: 药品说明书, 警示语, 预防措施, 自杀倾向, 抗抑郁药, 合理用药

Abstract: Objective To analyze the warning statements and preventive measures in the instructions of antidepressants in a tertiary mental health hospital in order to provide references for standardized wording in the instructions of antidep-ressants. Methods The frequency at which warning statements and preventive measures appeared in the instructions of antidepressants in the Affiliated Mental Hospital of Anhui Medical University from September 1 to September 30, 2022 was statistically analyzed. Results A total of 19 antidepressant instructions were included in the statistics. The total frequency of warning statements was 33, so was the total frequency of corresponding preventive measures. Among the 3 types of warning statements, the total frequency of instructions without corresponding warning statements was 10. The total frequency of complete warning statements was 17, compared with 22 for complete preventive meas-ures. Such warning statements as "Suicidal tendencies and antidepressants" appeared 30 times (90.91%), "Prohibited for patients with hepatitis B virus, hepatitis C virus, liver function impairment, or elevated transaminase levels above the normal upper limit" was used twice (6.06%), and "Prohibited for patients with epilepsy, glaucoma, urinary retention, recent history of myocardial infarction, or allergy to this product" turned up once (3.03%). The frequency of preventive measures corresponding to warning statements was 30 (90.91%) for preventive measures against "Suicidal tendencies and antidepressants", 2 (6.06%) for preventive measures related to Prohibited for patients with hepatitis B virus, hepatitis C virus, liver function impairment, or elevated transaminase levels above the normal upper limit", and 1(3.03%) for preventive measures relating to "Prohibited for patients with epilepsy, glaucoma, urinary retention, recent history of myocardial infarction, or allergy to this product". Conclusion There are inadequacies in the warning statements and preventive measures specified in instructions for antidepressants. It is recommended that related enterprises supplement the missing warning statements and preventive measures. As for the warning statements and preventive measures concerning "Suicidal tendencies and antidepressants", the age range of young patients prone to suicide should be clearly defined, and the contents of preventive measures should be improved.

Key words: Drug Instructions, Warning Statements, Preventive Measures, Suicidal Tendencies, Antidepressants, Rational Drug Use

中图分类号:

R971

邹远磊, 夏清荣, 梁俊, 何孔亮, 莫大明, 吴文宁. 抗抑郁药说明书警示语及预防措施分析[J]. 中国药物警戒, 2025, 22(3): 329-333.

ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning. Words of Warning and Preventive Measures in Labels of Antidepressants[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240826

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I3/329

参考文献

[1] NMPA. Administrative Decree No. 202. Notice on the Issuance of Specifications for the Specifications of Chemical Drugs and Biological Products(关于印发化学药品和生物制品说明书规范细则的通知)[EB/OL].(2006-05-10)[2023-01-02].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060510010101566_2.html.
[2] SAMR. Regulations on the administration of drug instructions and labels(药品说明书和标签管理规定)[EB/OL].(2006-03-15)[2023-01-02].https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html.
[3] ZHANG Y, YE Y.Excavation and Evaluation of Signals of Antide-pressant-Related Suicide Adverse Events[J].Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志) , 2019, 38(1): 43-50.
[4] WANG XP, LIU LR, LUO QF, et al.Research Progress on Adverse Reactions of Clinical Antidepressants[J].Journal of Taizhou University(台州学院学报),2022, 44(6): 71-77.
[5] STONE M, LAUGHREN T, JONES ML, et al.Risk of Suicidality in Clinical Trials of Antidepressants in Adults: Analysis of Proprietary Data Submitted to US Food and Drug Administration[J].BMJ, 2009, 339(7718): b2880.
[6] XIE HZ, DENG XL, XIE YR, et al.Guidelines for the Diagnosis and Treatment of Mental Disorders(2020 edition)(精神障碍诊疗规范2020年版)[M].First edition. Beijing: People's Medical Publishing House, 2020: 169-171.
[7] PAN J, ZHANG W, ZHONG LT, et al.Establishment of Suicide Intervention Mechanism for Inpatients[J].Modern Hospitals(现代医院),2021, 21(5): 701-703.
[8] WANG C, XU DM, SHAO J, et al.Expert Consensus of Suicide Care Interventions for Psychiatric Inpatients with Depression[J].Chinese Journal of Nursing(中华护理杂志),2022, 57(18): 2181-2185.
[9] LIANG YZ, ZHOU FZ.Research Progress in Nursing Care of Suicidal Depression Patients[J].Internal Medicine(内科),2020, 15(1): 67-69.
[10] WANG J, CHEN L, JI ZP, et al.Risk Factors to Suicide Risk in Misdiagnosed Bipolar Disorder II Treated for Major Depressive Disorder[J].Chinese Journal of Nervous and Mental Diseases(中国神经精神疾病杂志),2015, 41(2): 65-70.
[11] MANGIONE CM, BARRY MJ, NICHOLSON WK, et al.Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement[J].JAMA, 2022, 328(15): 1534-1542.
[12] American Academy of Pediatrics. 2022 Recommendations for Preventive Pediatric Health care[J].Pediatrics, 2022, 150(1): e2022058044.
[13] ZHANG Y, HU DY, DING XP, et al.A Meta-Analysis of the Incidence of Suicidal Ideation in Chinese Patients with Depression[J].Journal of Nursing Science(护理学杂志),2022, 37(9): 103-106.
[14] Chinese Medical Association.Guidelines for Primary Diagnosis and Treatment of Depression(2021)[J].Chinese Journal of General Practitioners(中华全科医师杂志),2021, 20(12): 1249-1260.
[15] ZWIEBEL SJ, VIGUERA AC.Discontinuing Antidepressants: Pearls and Pitfalls[J].Cleve Clin J Med, 2022, 89(1): 18-26.
[16] ZHANG B, WU H, ZHANG XM, et al.Strategies for Clinical Pharmaceutical Care Based on the Improvement of "Warnings" in Chinese Patent Medicine Instructions[J].Journal of Beijing University of Traditional Chinese Medicine(北京中医药大学报) , 2022, 45(10): 979-984.

抗抑郁药说明书警示语及预防措施分析

Words of Warning and Preventive Measures in Labels of Antidepressants

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	周坤, 马良, 李肇丰, 曹斌, 顾洪伟, 刘茜. 某市精神卫生中心安神类中成药用药分析[J]. 中国药物警戒, 2025, 22(2): 211-216.
[2]	聂晓璐, 孙凤, 阎爱侠, 彭晓霞, 詹思延. 基于多源信息构建药品不良反应基准数据库[J]. 中国药物警戒, 2025, 22(1): 10-15.
[3]	于玟路, 张虹. 马钱子在骨伤科的应用研究进展[J]. 中国药物警戒, 2025, 22(1): 116-120.
[4]	阿拉腾花, 王振兴, 张晓朦, 世伟, 席成伟, 王聪慧, 王立群, 张冰. 基于药品不良反应监测数据的心脏器官伤害风险信号挖掘分析[J]. 中国药物警戒, 2024, 21(7): 752-758.
[5]	赵暄, 郑婷婷, 李雪梅, 毛璐, 郭婧, 张威. 万古霉素不良反应报告分析[J]. 中国药物警戒, 2024, 21(7): 811-815.
[6]	张弦, 曲建昌, 赵强, 徐锌, 马瑞. 盐酸文拉法辛缓释胶囊致低钠血症1例分析[J]. 中国药物警戒, 2024, 21(7): 819-821.
[7]	孙雪林, 杜娇, 谭琴, 胡欣, 张亚同, 郑丽. 阿美替尼上市后不良反应分析[J]. 中国药物警戒, 2024, 21(6): 683-686.
[8]	时贯宏, 王淇, 孙昊, 陈雁杰, 储紫雁, 蒋傲, 汤在祥, 刘静芳. 基于美国FAERS数据库抗抑郁药物与胎儿及新生儿的不良事件信号分析[J]. 中国药物警戒, 2024, 21(6): 687-692.
[9]	李文鹏, 刘明煜, 曹颖, 周虎子威, 王胜锋. 阿片类药物全球滥用的监管现状及研究进展[J]. 中国药物警戒, 2024, 21(5): 513-518.
[10]	李文鹏, 周虎子威, 朱兰, 王胜锋. 阿片类药物需要量的估算方法及应用进展[J]. 中国药物警戒, 2024, 21(5): 519-523.
[11]	余馨, 贡磊磊, 姚伟洁, 袁偲偲, 冯欣. 中成药治疗复发性流产的临床研究概况性综述[J]. 中国药物警戒, 2024, 21(4): 361-365.
[12]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[13]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[14]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[15]	张龙瑛, 楼莉峰, 游倩, 魏语冰, 蔡艳, 李斌. 儿童和青少年抑郁障碍用药处方趋势及不良反应分析[J]. 中国药物警戒, 2024, 21(12): 1419-1424.